A sufficient efficacy in AD was not demonstrated for omalizumab and mepolizumab, reflecting the possible elusive role of IgE and eosinophils in the pathogenesis of clinical manifestations of AD. The gene discussed is IGHE; the disease is Alzheimer disease.